Literature DB >> 2821519

Org.2766 improves functional and electrophysiological aspects of regenerating sciatic nerve in the rat.

P De Koning1, W H Gispen.   

Abstract

The beneficial effect of short-term (8 days) melanocortin therapy on regenerating peripheral nerves is demonstrated using functional and electrophysiological tests. Following a crush lesion of the rat sciatic nerve, recovery of sensory function is monitored by assessing the responsiveness of the rat to a small electric current applied to the footsole. Recovery of motor function is assessed by means of an analysis of walking patterns. Normalization of the walking pattern reflects reinnervation of different muscle groups. The motor and H-reflex related sensory nerve conduction velocity of the regenerated nerves are longitudinally investigated in the same rats in which the recovery of motor and sensory function had been assessed previously. Functional tests show an enhanced recovery under melanocortin therapy, but in the end both saline- and melanocortin-treated rats show 100% recovery. However, when compared to the contralateral sciatic nerve, in the peptide-treated animals motor nerve conduction in the regenerated nerves has fully recovered after about 90 days following the crush lesion and the sensory conduction after about 120 days, whereas in the saline-treated rats a deficit of 20-40% in both motor and sensory conduction remains. This difference is observed even 214 days following crush.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2821519     DOI: 10.1016/0196-9781(87)90003-9

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  14 in total

1.  Reversal of experimental diabetic neuropathy by VEGF gene transfer.

Authors:  P Schratzberger; D H Walter; K Rittig; F H Bahlmann; R Pola; C Curry; M Silver; J G Krainin; D H Weinberg; A H Ropper; J M Isner
Journal:  J Clin Invest       Date:  2001-05       Impact factor: 14.808

2.  Treatment of diabetic polyneuropathy with the neurotrophic peptide ORG 2766.

Authors:  G D Valk; A C Kappelle; A M Tjon-A-Tsien; B Bravenboer; K Bakker; R P Michels; C M Groenhout; F W Bertelsmann
Journal:  J Neurol       Date:  1996-03       Impact factor: 4.849

3.  Randomized double-blind placebo-controlled trial to evaluate the effect of the ACTH4-9 analogue ORG 2766 in IDDM patients with neuropathy.

Authors:  B Bravenboer; P H Hendrikse; P L Oey; A C van Huffelen; C Groenhout; W H Gispen; D W Erkelens
Journal:  Diabetologia       Date:  1994-04       Impact factor: 10.122

Review 4.  FK506 and the role of immunophilins in nerve regeneration.

Authors:  B G Gold
Journal:  Mol Neurobiol       Date:  1997-12       Impact factor: 5.590

5.  Nasal administration of an ACTH(4-9) peptide analogue with dimethyl-beta-cyclodextrin as an absorption enhancer: pharmacokinetics and dynamics.

Authors:  N G Schipper; J C Verhoef; L M De Lannoy; S G Romeijn; J H Brakkee; V M Wiegant; W H Gispen; F W Merkus
Journal:  Br J Pharmacol       Date:  1993-12       Impact factor: 8.739

6.  Amelioration by the Ca2+ antagonist, nimodipine of an existing neuropathy in the streptozotocin-induced, diabetic rat.

Authors:  A C Kappelle; B Bravenboer; T van Buren; J Traber; D W Erkelens; W H Gispen
Journal:  Br J Pharmacol       Date:  1993-03       Impact factor: 8.739

7.  ACTH4-9 analogue ORG 2766 can improve existing neuropathy in streptozocin-induced diabetic rats.

Authors:  B Bravenboer; A C Kappelle; T van Buren; D W Erkelens; W H Gispen
Journal:  Acta Diabetol       Date:  1993       Impact factor: 4.280

8.  Lack of neuroprotection by an ACTH (4-9) analogue. A randomized trial in patients treated with vincristine for Hodgkin's or non-Hodgkin's lymphoma.

Authors:  S Koeppen; C C P Verstappen; R Körte; M E Scheulen; D Strumberg; T J Postma; J J Heimans; P C Huijgens; B Kiburg; K Renzing-Köhler; H C Diener
Journal:  J Cancer Res Clin Oncol       Date:  2004-01-16       Impact factor: 4.553

9.  Potential use of glutathione for the prevention and treatment of diabetic neuropathy in the streptozotocin-induced diabetic rat.

Authors:  B Bravenboer; A C Kappelle; F P Hamers; T van Buren; D W Erkelens; W H Gispen
Journal:  Diabetologia       Date:  1992-09       Impact factor: 10.122

10.  Cisplatin-induced neuropathy in mature rats: effects of the melanocortin-derived peptide ORG 2766.

Authors:  F P Hamers; C Pette; B Bravenboer; C J Vecht; J P Neijt; W H Gispen
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.